Tempest Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

TPST$0.36-5.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$30,268	$39,230
Prepaid expenses and other current assets	1,206	1,133
Total current assets	31,474	40,363
Property and equipment — net	886	840
Operating lease right-of-use assets	8,643	9,952
Other noncurrent assets	485	448
Total assets	$41,488	$51,603
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,450	$845
Accrued expenses	2,726	1,673
Current loan payable (net of discount and issuance costs of $74 and $112, respectively)	6,354	4,285
Current operating lease liabilities	869	952
Accrued compensation	1,762	1,543
Interest payable	59	113
Total current liabilities	14,220	9,411
Loan payable (net of discount and issuance costs of nil and $164, respectively)	—	6,264
Operating lease liabilities, less current portion	8,142	9,160
Total liabilities	22,362	24,835
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 43,971,622 and 22,045,255 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	44	22
Additional paid-in capital	226,188	192,009
Accumulated deficit	(207,106)	(165,263)
Total stockholders’ equity	19,126	26,768
Total liabilities and stockholders’ equity	$41,488	$51,603

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.